ABSENCE OF P53 AUTOANTIBODIES IN A SIGNIFICANT PROPORTION OF BREAST-CANCER PATIENTS

被引：28

作者：

VOJTESEK, B

KOVARIK, J

DOLEZALOVA, H

NENUTIL, R

HAVLIS, P

BRENTANI, RR

LANE, DP

机构：

[1] MASARYK MEM CANC INST,DEPT PATHOL,CR-65653 BRNO,CZECH REPUBLIC

[2] LUDWIG INST CANC RES,BR-015090 LIBERDALE,SP,BRAZIL

[3] UNIV DUNDEE,CANC RES CAMPAIGN LABS,DUNDEE DD1 4HN,SCOTLAND

来源：

BRITISH JOURNAL OF CANCER | 1995年 / 71卷 / 06期

关键词：

P53; BREAST CANCER; AUTOANTIBODIES;

D O I：

10.1038/bjc.1995.242

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We analysed antibodies specific for human p53 in sera from primary breast cancer patients using three different immunoassays and we related these results to the p53 level in tumour tissue detected by immunohistochemistry. Only 44% (11/25) of apparently enzyme-linked immunosorbent assay (ELISA)-positive sera were from patients with a high level of p53 protein in more than 50% of their tumour cells. Surprisingly, 36% (9/25) of the sera originated from patients with no detectable p53 protein at all. Immunoprecipitation data suggested that the reason for this discrepancy is that at least some of the antibodies detected as positive in the ELISA in these sera from patients with clinical stage I and stage II breast cancers may be induced by immunogens other than p53 protein. Many of these reactions give apparently positive signals in a variety of p53 assays, and very stringent analysis is required to avoid possible misinterpretation of these responses as a p53-specific B-cell response in human cancer patients.

引用

页码：1253 / 1256

页数：4

共 16 条

[1]

Allred D.C., Clark G.M., Elledge R., Fuqua S.A.W., Brown R.W., Chamness G.C., Osborne C.K., McGuire W.L., Association of p53 protein expression with tumour cell proliferation rate and clinical outcome of node-negative breast cancer, J. Natl Cancer Inst, 85, pp. 200-206, (1993)

[2]

Angelopoulou K., Diamandis E.P., Autoantibodies against the p53 tumor suppressor gene product quantified in cancer patient serum with time-resolved immunofluorometry, Cancer, 6, pp. 315-321, (1992)

[3]

Caron D.E., Fromentel C., Maylevin F., Mouriesse H., Lemerle J., Chandrasekaran K., May P., Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with b-cell lymphom, Int. J. Cance, 3, pp. 185-218, (1987)

[4]

Crawford L.V., Pim D.C., Bulbrook R.D., Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer, Int. J. Cancer, 30, pp. 403-408, (1982)

[5]

Davidoff A.M., Iglehart J.D., Marks J.R., Immune response to p53 is dependent upon p53 hsp70 complexes in breast cancers, Proc. Natl Acad. Sci. USA, 89, pp. 3439-3442, (1992)

[6]

Gannon J.V., Greaves R., Iggo R., Lane D.P., Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form, EMBO J., 9, pp. 1595-1602, (1990)

[7]

Harlow E.E., Lane D.P., Antibodies: A Laboratory Manual, (1988)

[8]

Hassapoglidou S., Diamandis E.P., Antibodies to the p53 tumour suppressor gene product quantified in cancer patient serum with a time-resolved immunofluorometric technique, Clin. Biochem, 25, (1992)

[9]

Hupp T.R., Meek D.W., Midgley C.A., Lane D.P., Regulation of the specific dna binding function of p53, Cell, 71, pp. 875-886, (1992)

[10]

Lubin R., Schlichtholz B., Bengoufa D., Zalcman G., Tredaniel J., Hirsch A., Caron De Fromentel C., Preudhomme C., Fenaux P., Fournier G., Mangin P., Laurentpuig P., Pelletier G., Schlumberger M., Desgrand-Champs F., Le Duc A., Peyrat J.P., Janin N., Bressac B., Soussi T., Analysis of p53 antibodies in patients with various cancer define bncell epitopes of human p53: Distribution on primary structure and exposure on protein surface, Cancer Res, 53, pp. 5872-5876, (1993)

← 1 2 →